Piroxicam-β-cyclodextrin: a GI safer piroxicam

Area of Science:

• Pharmacology
• Gastroenterology
• Drug Development

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for their anti-inflammatory and analgesic properties.
• However, NSAID use is linked to severe adverse effects, particularly gastrointestinal (GI) complications like ulcers and bleeding.
• Cardiovascular (CV) risks associated with NSAIDs further complicate treatment choices.

Purpose of the Study:

• To explore strategies for developing NSAIDs with reduced gastrointestinal toxicity.
• To evaluate the efficacy and safety of piroxicam-β-cyclodextrin (PBC) as a GI-safer alternative to conventional piroxicam.

Main Methods:

• Review of preclinical and clinical data on piroxicam-β-cyclodextrin (PBC).
• Analysis of mechanisms underlying NSAID-induced GI damage, including COX inhibition and physicochemical effects.
• Comparison of GI tolerability and pharmacokinetic profiles of PBC versus uncomplexed piroxicam.

Main Results:

• NSAID-induced GI damage results from disruption of mucosal defenses and COX inhibition.
• Complexation with β-cyclodextrin significantly reduces the gastrotoxicity of piroxicam.
• PBC demonstrates improved upper GI tolerability, faster absorption, and quicker onset of analgesic action compared to piroxicam.
• PBC exhibits a favorable GI safety profile and is considered CV safe.

Conclusions:

• Developing NSAIDs with enhanced GI tolerability is crucial for patient safety.
• Piroxicam-β-cyclodextrin (PBC) represents a significant advancement, offering effective anti-inflammatory and analgesic properties with improved GI safety.
• PBC is a valuable therapeutic option for patients requiring NSAID treatment, providing a safer alternative to uncomplexed piroxicam.